Compare NVMI & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVMI | PODD |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 10.2B |
| IPO Year | 2001 | 2007 |
| Metric | NVMI | PODD |
|---|---|---|
| Price | $381.32 | $132.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | ★ $431.88 | $341.48 |
| AVG Volume (30 Days) | 420.9K | ★ 1.3M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.67 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $20.94 | $24.55 |
| Revenue Next Year | $19.53 | $19.18 |
| P/E Ratio | $56.79 | ★ $49.30 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $266.43 | $126.40 |
| 52 Week High | $615.99 | $354.88 |
| Indicator | NVMI | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 54.37 | 34.12 |
| Support Level | $356.50 | $131.24 |
| Resistance Level | $387.71 | $153.33 |
| Average True Range (ATR) | 10.88 | 4.18 |
| MACD | 4.78 | -0.40 |
| Stochastic Oscillator | 89.15 | 9.57 |
Nova Ltd is a provider of metrology and process control solutions used in semiconductor manufacturing. The company provides high-performance metrology solutions across the semiconductor fabrication lifecycle and develops differentiated inline metrology solutions deployed by a broad range of customers, including integrated circuit manufacturers. Its portfolio combines high-precision hardware and software, enabling customers to improve device performance, enhance yields, and accelerate time to market. Its products include Dimensional Metrology, Materials Metrology, Chemical Metrology, and Software Solutions. The company operates in China, Taiwan, R.O.C., the United States and other regions, with maximum revenue coming from China.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.